Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Cash from Operations (2016 - 2025)

CytomX Therapeutics' Cash from Operations history spans 12 years, with the latest figure at 23243000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 16.75% year-over-year to 23243000.0; the TTM value through Dec 2025 reached 75587000.0, up 12.34%, while the annual FY2025 figure was 75587000.0, 12.34% up from the prior year.
  • Cash from Operations reached 23243000.0 in Q4 2025 per CTMX's latest filing, down from 15548000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 9349000.0 in Q1 2023 to a low of 41313000.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 22383600.0, with a median of 22603000.0 recorded in 2023.
  • The largest YoY upside for Cash from Operations was 122.63% in 2023 against a maximum downside of 1476.67% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 31192000.0 in 2021, then skyrocketed by 95.53% to 1393000.0 in 2022, then tumbled by 1476.67% to 21963000.0 in 2023, then rose by 9.36% to 19908000.0 in 2024, then decreased by 16.75% to 23243000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Cash from Operations are 23243000.0 (Q4 2025), 15548000.0 (Q3 2025), and 15753000.0 (Q2 2025).